Supporting the thesis that high IL-6 baseline levels imply a poorer outcome was concluded after a Phase II clinical trial by Dorff et al. in which Siltuximab, a Monoclonal Antibody against Interleukin 6 in pre-treated patients with prostate cancer, was applied [38]. The gene discussed is IL6; the disease is prostate carcinoma.